BlackRock’s VYNE Therapeutics VYNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$73.3K Sell
44,405
-38,174
-46% -$63K ﹤0.01% 4836
2025
Q1
$130K Sell
82,579
-735
-0.9% -$1.16K ﹤0.01% 4652
2024
Q4
$279K Buy
83,314
+245
+0.3% +$821 ﹤0.01% 4503
2024
Q3
$156K Buy
83,069
+22,488
+37% +$42.3K ﹤0.01% 4528
2024
Q2
$119K Buy
60,581
+15,963
+36% +$31.4K ﹤0.01% 4612
2024
Q1
$137K Sell
44,618
-2,679
-6% -$8.23K ﹤0.01% 4608
2023
Q4
$110K Buy
47,297
+2,358
+5% +$5.49K ﹤0.01% 4705
2023
Q3
$182K Sell
44,939
-4,171
-8% -$16.9K ﹤0.01% 4639
2023
Q2
$201K Hold
49,110
﹤0.01% 4644
2023
Q1
$151K Sell
49,110
-103
-0.2% -$317 ﹤0.01% 4777
2022
Q4
$133K Sell
49,213
-82
-0.2% -$221 ﹤0.01% 4875
2022
Q3
$197K Sell
49,295
-128
-0.3% -$512 ﹤0.01% 4890
2022
Q2
$346K Sell
49,423
-6,277
-11% -$43.9K ﹤0.01% 4790
2022
Q1
$652K Sell
55,700
-264
-0.5% -$3.09K ﹤0.01% 4712
2021
Q4
$1.03M Sell
55,964
-1,662
-3% -$30.5K ﹤0.01% 4589
2021
Q3
$1.44M Sell
57,626
-23
-0% -$575 ﹤0.01% 4386
2021
Q2
$3.64M Sell
57,649
-142,727
-71% -$9.02M ﹤0.01% 3945
2021
Q1
$24.7M Buy
200,376
+33,865
+20% +$4.17M ﹤0.01% 3017
2020
Q4
$18.9M Buy
166,511
+29,769
+22% +$3.39M ﹤0.01% 2970
2020
Q3
$16.3M Buy
136,742
+22,665
+20% +$2.71M ﹤0.01% 2906
2020
Q2
$14.2M Buy
114,077
+72,916
+177% +$9.08M ﹤0.01% 2934
2020
Q1
$7.94M Buy
41,161
+27,885
+210% +$5.38M ﹤0.01% 3067
2019
Q4
$4.44M Buy
13,276
+123
+0.9% +$41.1K ﹤0.01% 3493
2019
Q3
$4.24M Buy
13,153
+476
+4% +$154K ﹤0.01% 3487
2019
Q2
$5.47M Buy
12,677
+3,917
+45% +$1.69M ﹤0.01% 3465
2019
Q1
$4.95M Buy
8,760
+1,098
+14% +$621K ﹤0.01% 3384
2018
Q4
$2.27M Buy
7,662
+328
+4% +$97.3K ﹤0.01% 3597
2018
Q3
$5.2M Buy
7,334
+1,037
+16% +$735K ﹤0.01% 3455
2018
Q2
$3.68M Sell
6,297
-54
-0.9% -$31.6K ﹤0.01% 3523
2018
Q1
$17.2M Buy
+6,351
New +$17.2M ﹤0.01% 2831